On January 24, new data was published from a Phase 1 clinical trial of Arcov, China’s most advanced mRNA vaccine candidate (China.Table reported). According to the data, “high concentrations of neutralizing antibodies against live SARS-CoV-2” were found in most subjects after two vaccinations. No severe side effects were recorded. However, the scientists also stated that it is still too early to accurately assess its efficacy.
Continue reading now
Get 30 days of free access to the Professional Briefing to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now